CD47 Targeting Therapeutics Market Key Players Analysis - Conjupro biotherapeutics (US), EpicentRx (US), Forty Seven (US),ImmuneOncia Therapeutics (Korea),ImmuneOnco Biopharmaceuticals (China).

CD47 Targeting Therapeutics Market Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "CD47 Targeting Therapeutics Market By Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers, Other Diseases Indications), By Type of molecule(Biologics, Small molecule) - Market Outlook and Industry Analysis 2030"

According to the most recent analysis by InsightAce Analytic, the worldwide CD47 targeted therapeutics market is predicted to grow at a promising CAGR of 67% between 2022 and 2030.

Get Free Access to Demo Report, Excel Pivot and ToC : www.insightaceanalytic.com/request-sample/1290

Overexpression of the immunoglobulin CD47 is a critical mechanism of tumor cell immune evasion. CD47 is a transmembrane protein that glycosylates on the surface of cancer cells and aids in their survival in a variety of cancer types. When CD47 binds to SIRPα, it establishes an inhibitory signaling cascade that stops malignant cells from being phagocytosed by macrophages. This occurs in various cancer types. Inhibiting the CD47-SIRPα signaling pathway can increase tumor cell phagocytosis by macrophages.
Several factors contribute to the growth of the global CD47 targeting therapeutics market, including increased adoption of CD47-targeting anti-cancer therapies, an aging population, a high prevalence of various cancer types, and growing public awareness of the benefits of targeting therapeutics.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

Furthermore, growing R&D efforts to increase knowledge of CD47-dependent signalling are expected to open up new prospects for the CD47 targeted therapeutics market throughout the forecast period. Improved knowledge in this field of research could lead to the development of advanced and effective anti-tumor medicines that suppress CD47 signaling in cancer cells. In June 2021, Trillium Therapeutics Inc. (Canada) developed TTI-621 (SIRPα-IgG1 Fc), a checkpoint inhibitor for the innate immune system, in conjunction with doxorubicin. TTI-621 inhibits macrophage phagocytosis by binding to CD47, an immunological checkpoint that binds SIRPα and sends a "don't eat me" signal.
However, the high cost and complexity of target therapies, damage to normal cells while exerting an anti-tumor impact, and stringent government restrictions for therapeutic approvals are projected to hinder market adoption in the projection years.

According to the report, the North America region is predicted to increase significantly over the projection period (2022-2030) due to the rapid adoption of innovative pharmaceuticals and therapy procedures, as well as the increasing number of cancer patients and deaths in this region.

Unlock Your GTM Strategy:www.insightaceanalytic.com/customisation/1290

Major market players operating in the CD47 targeting therapeutics market include Abpro (US), ALX Oncology (US), Apmonia Therapeutics (France), Arch Oncology (US), Aurigene (Bangalore), Bristol Myers Squibb (US), Conjupro biotherapeutics (US), EpicentRx (US), Forty Seven (US) TG Therapeutics, Adagene, Alector, Inc., Apmonia Therapeutics, I-MAB Biopharma Co., Ltd., QLSF Biotherapeutics Inc., Phanes Therapeutics, Inc., Bio-Thera Solutions, among others.

Key developments in the market:
• In Jan 2022, the American Food and Drug Administration gave the next-generation CD47 blocker evorpacept, made by ALX Oncology, was given orphan drug designation ("ODD") for the treatment of patients with gastric cancer and gastroesophageal junction cancer.

• In Sept 2021, Pfizer Inc. (US) acquired Trillium Therapeutics Inc. (Canada) with its CD47 candidates for US$2.3 billion. This acquisition has enhanced the oncology and haematology portfolios of Pfizer.

• In June 2021, ALX Oncology (US) entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company (US), an American pharmaceutical company, to evaluate the combination of ALX148, a next-generation CD47 blocker, and CYRAMZA (ramucirumab), Lilly's anti-VEGFR2 antibody, for the treatment of gastric cancer.

• In Mar 2020, Alector and Innovent Biologics entered into a licencing agreement so that AL008 could be developed and sold in China for oncology indications. The CD47-SIRP-alpha pathway, a potent survival pathway used by tumours to evade the innate immune system, is the target of AL008, a novel antibody product candidate.

• In Mar 2020, Gilead Sciences, Inc. and Forty Seven, Inc. announced that they have entered into a stratigic agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash.

Market Segments
CD47 Targeting Therapeutics Market, by Target Disease Indication, 2022-2030 (Valu US$ Mn)
• Acute Myeloid Leukemia
• Non-Hodgkin Lymphoma
• Colorectal Cancer
• Diffuse Large B-cell Lymphoma
• Myelodysplastic Syndromes
• Non-Small Cell Lung Cancers
• Ovarian Epithelial Cancer
• Oral mucositis
• Small Cell Lung Cancers
• Other Diseases Indications
CD47 Targeting Therapeutics Market, by Type of Molecule, 2022-2030 (Value US$ Mn)
• Biologics
• Small Molecule
CD47 Targeting Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ www.insightaceanalytic.com/buy-report/1290

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.